Navigation Links
Ibrutinib Monotherapy Clinical Trial Data in Patients with Waldenstrom's Macroglobulinemia Presented at the International Conference on Malignant Lymphoma in Lugano, Switzerland
Date:6/20/2013

lity and terms of any such financing, the safety and/or efficacy results of clinical trials of our product candidates, our failure to obtain regulatory approvals or comply with ongoing governmental regulation, our ability to commercialize, manufacture and achieve market acceptance of any of our product candidates, for which we rely heavily on collaboration with third parties, and our ability to protect and enforce our intellectual property rights and to operate without infringing upon the proprietary rights of third parties. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, performance or achievements and no assurance can be given that the actual results will be consistent with these forward-looking statements. For more information about the risks and uncertainties that may affect our results, please see the Risk Factors section of our filings with the Securities and Exchange Commission, including our transition report on Form 10-K for the six month period ended December 31, 2012 and quarterly reports on Form 10-Q. We do not intend to update any of the forward-looking statements after the date of this announcement to conform these statements to actual results, to changes in management's expectations or otherwise, except as may be required by law.

References

[1] Pub Med Health. Waldenstrom's macroglobulinemia; macroglobulinemia - primary; Lymphoplasmacytic lymphoma. Available from: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001614/. Accessed May 14, 2013.

[2] American Cancer Society. Waldenstrom macroglobulinema. Available from: http://www.cancer.org/acs/groups/cid/documents/webcontent/003148-pdf.pdf. Accessed May 14, 2013.

[3] Garcia-Sanz R, Ocio E. Novel treatment regimens for Waldenstrom's
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine
2. Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine
3. Updated Results of Two Phase 2 Ibrutinib Studies in Patients with Mantle Cell Lymphoma or Diffuse Large B-cell Lymphoma
4. Ibrutinib Phase 2 Data: Analyses Show Efficacy with Ibrutinib Monotherapy in Patients with Relapsed or Refractory Mantle Cell or Diffuse Large B-cell Lymphoma
5. Ibrutinib Expanded Access Program Open to Eligible U.S. Patients with Relapsed or Refractory Mantle Cell Lymphoma
6. Phase II Ibrutinib Monotherapy Study Shows CLL Patients Achieved Rapid and Sustainable Disease Control Irrespective of Age or High Risk Prognostic Factor
7. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
8. Ibrutinib Receives Two Oncology Breakthrough Therapy Designations from U.S. Food and Drug Administration
9. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
10. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
11. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... 2014 - New Solution That ... JIN Co., Ltd. will launch JINS MEME "ACADEMIC ... 500,000 yen or $5,000 (without tax /including two pairs of ... is a dedicated solution of "JINS MEME" to academic researchers, ... data* generated by electrooculography and six-axis sensors without API. (*Physiological ...
(Date:11/26/2014)... 2014  Aethlon Medical, Inc. (OTCQB:AEMD), announced today that ... approximately $3.3 million at a price of $0.30 per ... focused investor. Each unit consists of one common share ... warrant. Each whole warrant entitles the holder to acquire ... a period of five years from closing.  ...
(Date:11/26/2014)... 2014  Genomic Health, Inc. (Nasdaq: GHDX ) ... Executive Officer and President, will participate in the 26 ... New York Palace Hotel in New York ... Eastern Time (ET). To access the live ... to the  Investor Relations  section of the company,s web ...
Breaking Medicine Technology:JIN to Launch JINS MEME ACADEMIC PACK in Late April 2015 2JIN to Launch JINS MEME ACADEMIC PACK in Late April 2015 3Aethlon Medical Announces $3.3 Million Equity Investment 2Aethlon Medical Announces $3.3 Million Equity Investment 3Genomic Health to Present at the 26th Annual Piper Jaffray Healthcare Conference 2Genomic Health to Present at the 26th Annual Piper Jaffray Healthcare Conference 3
... 8 Alpharma Inc. (NYSE: ALO ... results from,clinical trials that showed ALO-01 (EMBEDA(TM)) ... clinically relevant features addressing abuse liability,alongside a ... I and II,studies, presented at the 27th ...
... Annual Meeting of the American Pain Society ... ... with lacosamide,demonstrated sustained pain relief from diabetic neuropathic pain (DNP),compared to placebo-treated ... Pain Society (APS) in Tampa, Fla., "This is the first placebo-controlled ...
Cached Medicine Technology:Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session 2Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session 3Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session 4Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session 5Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session 6Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session 7New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain 2New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain 3New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain 4
(Date:11/28/2014)... November 28, 2014 The ... growth over the past five years. The industry ... of therapies that are either alternative to conventional ... to IBISWorld industry analyst David Whytcross, “industry revenue ... and growing private health insurance membership.” Meanwhile, improving ...
(Date:11/28/2014)... 28, 2014 Written and narrated by award ... Voices releases the “The Happiest Man In the World: ... account of how and why Project C.U.R.E. came to be. ... mother Josie and the Reverend Richard W. Jackson, Dr. Jackson ... of 30, but realized that he wasn’t happy. Prompted by ...
(Date:11/28/2014)... -- Planning on seconds at Thanksgiving Day dinner this year? ... gastroesophageal reflux disease (GERD) -- a few steps may help ... and throat specialist at Lenox Hill Hospital in New York ... Thanksgiving: Pace yourself. Rather than have ... the day. It,s also a good idea to have a ...
(Date:11/28/2014)... Not only is the Éminence Organic Skin ... parabens and other cancer-causing agents, but they are also ... awareness programs that help in the fight against breast ... an incredible, record-breaking contribution of $30,000 through participation in ... Sweet Red Rose Whip Moisturizer and the company’s corporate ...
(Date:11/28/2014)... An inventor and dental assistant from Kent, ... filling and it was almost impossible to reach. "This gave ... said. , The patent-pending Access Light allows for easier use ... of the mouth, as well as avoids harm to the ... to use and clean, it also helps prevent cross-contamination. , ...
Breaking Medicine News(10 mins):Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 4Health News:Thanksgiving Weekend Audiobook Treat! “The Happiest Man In the World: Life Lessons From a Cultural Economist” by Dr. James W. Jackson 2Health News:Don't Let Chronic Heartburn Spoil Your Thanksgiving Feast 2Health News:Éminence Organic Skin Care Donates Record-breaking $30,000 to Breast Cancer Research 2Health News:Éminence Organic Skin Care Donates Record-breaking $30,000 to Breast Cancer Research 3
... toll from the mosquito-borne virus has risen to six in ... died of the disease in the paediatric ward of King ... the Farrukhabad district hospital,' V.S. Nigam, health department spokesman told ... cases has shot up to 199 in the state with ...
... villager suffering from a serious kidney ailment died Saturday ... hospital here//, apparently because he could not afford the ... a window of the nephrology ward of the Sanjay ... was being treated, hospital sources told IANS. ...
... lowered cholesterol levels are beneficial for the heart is ... the risk of prostate cancer// for men has only ... convinced that the two conditions are related, proving that ... prostate, too. ,Dr. William J. Catalona, director of ...
... Nile virus evades the body’s immune defenses by blocking ... could pave the way for a vaccine// to protect ... Medical Center researchers report. ,Researchers discovered the receptor’s ... a study, described in October’s Journal of Virology that ...
... Although Offensive breath is a common malady that many suffer ... scenario. In an all out effort to overcome it those ... food stuffs, which are notably notorious in causing bad breath//. ... cover it up, chewing gums, and mouth rinses are usually ...
... caught between the devil and the deep sea, unable to ... of emergency mental// healthcare. The patient, a 17 year old ... form of counseling was attempted. ,The girl suffered ... suicide attempts. According to the mother, her daughter was ...
Cached Medicine News:Health News:Cholesterol Levels affects Risk of Prostate Cancer 2Health News:Study Unveils West Nile Virus Immune Evasion, Points to Vaccine Development 2Health News:Study Unveils West Nile Virus Immune Evasion, Points to Vaccine Development 3
... has the right product for any patient ... intubated patients to patients with tracheotomies. These ... and critical care applications., ,The Unti-Mist ... patients and staff members. This entire product ...
Passive heat and moisture exchangers for respiratory applications....
Passive heat and moisture exchangers for respiratory applications....
Ballard trach care HMES and filters, tv 1500, HME...
Medicine Products: